{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"4.2","value":"4.2"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"5.3","value":"4.6"},{"groupId":"OG002","lowerLimit":"5.9","upperLimit":"5.9","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Median (min,max) ratio of XPO1 mRNA expression after treatment to pre-treatment by study part, schema, and dose","dispersionType":"Full Range","groups":[{"description":"45 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG000","title":"Part A: Weekly Dose Level 1 (WDL 1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG001","title":"Part B: Weekly Dose Level -1 (WDL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG002","title":"Part PK: Weekly Dose Level -1 (WDL -1)"}],"paramType":"MEDIAN","populationDescription":"high-grade glioma (HGG) patients with data available","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Pharmacodynamics of Selinexor in High-grade Glioma (HGG) Patients","type":"SECONDARY","unitOfMeasure":"Ratio of XPO1 mRNA expression"}